A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2

Reed, 2008, Bcl-2 family proteins and cancer, Oncogene, 27, 6398, 10.1038/onc.2008.307

Weinberg, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013

Strasser, 2008, The Bcl-2 protein family: opposing activities that mediate cell death, Nat Rev Mol Cell Biol, 9, 47, 10.1038/nrm2308

Green, 2010, The BCL-2 family reunion, Mol Cell, 37, 299, 10.1016/j.molcel.2010.01.025

Fesik, 2008, ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor, Cancer Res, 68, 3421, 10.1158/0008-5472.CAN-07-5836

Lam, 2013, ABT-9, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets, Nat Med, 19, 202, 10.1038/nm.3048

Letai, 2008, Diagnosing and exploiting cancer’s addiction to blocks in apoptosis, Nat Rev Cancer, 8, 121, 10.1038/nrc2297

Letai, 2013, ABT-199: taking dead aim at BCL-2, Cancer Cell, 23, 139, 10.1016/j.ccr.2013.01.018

Cory, 2013, ABT-199, a new Bcl-2-specific BH3 mimetic, hasefficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia, Blood, 121, 2285, 10.1182/blood-2013-01-475855

Distelhorst, 2014, Bcl-2 regulation of the inositol 1,4,5-trisphosphate receptor and calcium signaling in normal and malignant lymphocytes: Potential new target for cancer treatment, Biochim Biophys Acta, 1843, 2205, 10.1016/j.bbamcr.2014.03.008

Bultynck, 2014, A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum, Biochim Biophys Acta, 1843, 2240, 10.1016/j.bbamcr.2014.04.017

Distelhorst, 2014, Feedback regulation mediated by Bcl-2 and DARPP-32 regulates inositol 1,4,5-trisphosphate receptor phosphorylation and promotes cell survival, Proc Natl Acad Sci U S A, 111, 1186, 10.1073/pnas.1323098111

Distelhorst, 2009, The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IPreceptor, Proc Natl Acad Sci, 106, 14397, 10.1073/pnas.0907555106

Bultynck, 2012, Selective regulation of IP(3)-receptor-mediated Ca(2+) signaling and apoptosis by the BH4 domain of Bcl-2 versus Bcl-Xl, Cell Death Differ, 19, 295, 10.1038/cdd.2011.97

Distelhorst, 2008, Targeting Bcl-2-IPreceptor interaction to reverse Bcl-2′s inhibition of apoptotic calcium signals, Mol Cell, 31, 255, 10.1016/j.molcel.2008.06.014

Distelhorst, 2011, Induction of Ca-driven apoptosis in chronic lymphocytic leukemia cells by peptide-mediated disruption of Bcl-2-IPreceptor interaction, Blood, 117, 2924, 10.1182/blood-2010-09-307405

Bultynck, 2013, IP3R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IPR-derived peptide targeting the BH4 domain of Bcl-2, Cell Death Dis, 4, e632, 10.1038/cddis.2013.140

Amiot, 2005, Melphalan-induced apoptosis in multiple myeloma cells is associated with a cleavage of Mcl-1 and Bim and a decrease in the Mcl-1//Bim complex, Oncogene, 24, 8076, 10.1038/sj.onc.1208949

Xu, 2013, A review of the role of Puma, Noxa and Bim in the tumorigenesis, therapy and drug resistance of chronic lymphocytic leukemia, Cancer Gene Ther, 20, 1, 10.1038/cgt.2012.84

Letai, 2007, Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737, J Clin Invest, 117, 112, 10.1172/JCI28281

Crabtree, 2006, Thymocyte negative selection is mediated by protein kinase C- and Ca-dependent transcriptional induction of Bim of cell death, J Immunol, 176, 2299, 10.4049/jimmunol.176.4.2299

Al-Katib, 1993, A unique EBV-negative low-grade lymphoma line (WSU-FSCCL) exhibiting both t(14, 18) and t(8;11), Cancer Genetics and Cytogenetics, 70, 62, 10.1016/0165-4608(93)90132-6

Amiot, 2014, The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11, 14) multiple myeloma, Leukemia, 28, 210, 10.1038/leu.2013.216

Pellat-Deceunynck, 2011, A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines, Haematologica, 96, 574, 10.3324/haematol.2010.033456

Strasser, 1999, Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity, Science, 286, 1735, 10.1126/science.286.5445.1735

Distelhorst, 2003, Microarray analysis uncovers the induction of the proapoptotic BH3-only protein Bim in multiple models of glucocorticoid-induced apoptosis, J Biol Chem, 278, 23861, 10.1074/jbc.M301843200

Insel, 2004, The pro-apoptotic protein Bim is a convergence point for cAMP/protein kinase A- and glucocorticoid-promoted apoptosis in lymphoid cells, J Biol Chem, 279, 20858, 10.1074/jbc.M310643200

Villunger, 2005, BH3-only proteins Puma and Bim are rate-limiting for gamma-radiation- and glucocorticoid-induced apoptosis of lymphoid cells, Blood, 106, 4131, 10.1182/blood-2005-04-1595

Eldering, 2015, BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future, Oncogene, 34, 2426, 10.1038/onc.2014.181

Byrd, 2011, Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765, Blood, 117, 6287, 10.1182/blood-2011-01-328484

Spaargaren, 2012, The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia, Blood, 119, 2590, 10.1182/blood-2011-11-390989

Wang, 2014, BTK inhibition targetsCLL proliferation through its effects on B-cell receptor signaling activity, Leukemia, 28, 649, 10.1038/leu.2013.358

Sanford, 2014, Ibrutinib: First Global Approval, Drugs, 74, 263, 10.1007/s40265-014-0178-8

Zhan, 2015, Bruton Tyrosine Kinase Is a Therapeutic Target in Stem-like Cells from Multiple Myeloma, Cancer Research, 75, 594, 10.1158/0008-5472.CAN-14-2362

Anderson, 2012, Bruton’s tyrosine kinase: oncotarget in myeloma, Oncotarget, 3, 2012

Wang, 2014, Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells, British Journal of Haematology, 166, 849, 10.1111/bjh.12974

Zhu, 2014, Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment, Cancer Cell International, 14, 32, 10.1186/1475-2867-14-32

Lozanski, 2014, Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib, New England Journal of Medicine, 370, 2286, 10.1056/NEJMoa1400029

Wang, 2014, Ibrutinib Resistance in Chronic Lymphocytic Leukemia, New England Journal of Medicine, 370, 2352, 10.1056/NEJMc1402716

Byrd, 2015, Hypermorphic mutation of phospholipase C, gamma 2 acquired in ibrutinib resistant CLL confers BTK independency upon BCR activation, Blood, 126, 61, 10.1182/blood-2015-02-626846

Nilsson, 1992, Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells, Blood, 79, 495, 10.1182/blood.V79.2.495.495

Buggy, 2010, The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy, Proc Natl Acad Sci USA, 107, 13075, 10.1073/pnas.1004594107

Fowler, 2013, Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies, J Clin Oncol, 31, 88, 10.1200/JCO.2012.42.7906

Flynn, 2013, Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes, Blood, 122, 2539, 10.1182/blood-2013-06-507947

Levy, 2015, Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK, Proc Natl Acad Sci USA, 112, E966, 10.1073/pnas.1500712112

Chang, 2013, Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms, Oncotarget, 4, 2013

Bornhäuser, 2015, Multiple myeloma, The Lancet, 385, 2197, 10.1016/S0140-6736(14)60493-1

Cheson, 2014, How we manage follicular lymphoma, Leukemia, 28, 1388, 10.1038/leu.2014.91

Anderson, 2007, A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma, Oncogene, 26, 2374, 10.1038/sj.onc.1210028

Kumar, 2007, ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells, Leukemia, 21, 1549, 10.1038/sj.leu.2404719

Wen, 2007, The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan, Clin Cancer Res, 13, 621, 10.1158/1078-0432.CCR-06-1526

Amiot, 2011, ABT-737 is highly effective against molecular subgroups of multiple myeloma, Blood, 118, 3901, 10.1182/blood-2010-11-317438

Distelhorst, 2004, Bcl-2 functionally interacts with inositol 1,4,5-trisphosphate receptors to regulate calcium release from the ER, J Cell Biol, 166, 193, 10.1083/jcb.200309146

Cook, 2008, Casignalling checkpoints in cancer: remodelling Cafor cancer cell proliferation and survival, Nat Rev Cancer, 8, 361, 10.1038/nrc2374

Shuba, 2011, Calcium in tumour metastasis: new roles for known actors, Nat Rev Cancer, 11, 609, 10.1038/nrc3105

Roberts-Thomson, 2007, Calcium and cancer: targeting Catransport, Nat Rev Cancer, 7, 519, 10.1038/nrc2171

Wang, 2015, High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia, Oncotarget, 6, 5299, 10.18632/oncotarget.3024

Lee, 2012, Inhibition of Bax protects neuronal cells from oligomeric A β neurotoxicity, Cell Death Dis, 3, e309, 10.1038/cddis.2012.43

Distelhorst, 2012, Acidosis Promotes Bcl-2 Family Mediated Evasion of Apoptosis: Involvement of Acid-Sensing G Protein-Coupled Receptor GPR65 Signaling to MEK/ERK, J Biol Chem, 287, 27863, 10.1074/jbc.M112.384685